Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$840.46 +20.61 (+2.51%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$840.55 +0.09 (+0.01%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $825, reflecting a significant increase of 8.2% recently, indicating strong market performance.
  • Analysts have a consensus rating of "Moderate Buy" with a target price averaging around $939.61, suggesting potential for further appreciation.
  • Insider buying activity has been notable, with the CEO purchasing shares, which can signal confidence in the company's future prospects.

Cons of Eli Lilly and Company

  • The stock has a high P/E ratio of 53.98, which may indicate that it is overvalued compared to its earnings, posing a risk for new investors.
  • Recent downgrades from some analysts, including a shift to a "neutral" rating, suggest mixed opinions on the stock's future performance.
  • The company has a debt-to-equity ratio of 1.86, which indicates a higher level of debt compared to equity, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$794.90 billion
P/E Ratio
54.93
Consensus Rating
Moderate Buy
Consensus Price Target
$938.94 (+11.7% Upside)
Volume
5.08 million shares
Average Volume
3.98 million shares
Today's Range
$816.10
$848.13
50-Day Range
$625.15
$840.46
52-Week Range
$623.78
$937.00
Dividend Yield
0.71%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$188.50 +2.53 (+1.36%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$188.74 +0.24 (+0.12%)
As of 10/3/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $185.40, reflecting a positive market sentiment and potential for growth.
  • Johnson & Johnson has a consensus rating of "Moderate Buy," indicating that analysts believe the stock is a good investment opportunity.
  • The company has a strong market capitalization of approximately $446.51 billion, suggesting stability and a solid position in the healthcare sector.

Cons of Johnson & Johnson

  • Recent insider selling, including a significant transaction by an executive vice president, may raise concerns about the company's short-term outlook.
  • The stock has experienced fluctuations, with a 52-week low of $140.68, indicating potential volatility that could affect investment returns.
  • With a P/E ratio of 19.83, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$454.31 billion
P/E Ratio
20.16
Consensus Rating
Moderate Buy
Consensus Price Target
$188.88 (+0.2% Upside)
Volume
8.67 million shares
Average Volume
8.88 million shares
Today's Range
$186.91
$189.78
50-Day Range
$164.76
$188.51
52-Week Range
$140.68
$189.78
Dividend Yield
2.76%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$234.06 -2.50 (-1.05%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$233.48 -0.59 (-0.25%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $244.77, reflecting a significant increase of 5.7% recently, indicating positive market sentiment.
  • AbbVie has received multiple upgrades from analysts, with several firms raising their price targets, suggesting strong future growth potential.
  • The company has a robust pipeline of products, which is expected to drive profits and growth in the coming years.

Cons of AbbVie

  • Recent insider selling, including a significant transaction by an executive vice president, may raise concerns about the company's future performance.
  • AbbVie has a high price-to-earnings ratio of 116.56, which could indicate that the stock is overvalued compared to its earnings.
  • The company has a relatively low current ratio of 0.74, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$413.22 billion
P/E Ratio
111.46
Consensus Rating
Moderate Buy
Consensus Price Target
$228.22 (-2.5% Downside)
Volume
6.55 million shares
Average Volume
6.21 million shares
Today's Range
$233.71
$238.84
50-Day Range
$188.47
$244.77
52-Week Range
$163.81
$244.81
Dividend Yield
2.80%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$360.17 +6.45 (+1.82%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$360.74 +0.57 (+0.16%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $395, reflecting a strong upward adjustment from previous targets, indicating positive market sentiment.
  • UnitedHealth Group has a consensus rating of "Moderate Buy" from analysts, suggesting that many believe the stock has potential for growth.
  • The company reported a significant year-over-year revenue increase of 12.9%, showcasing its strong market position and operational efficiency.

Cons of UnitedHealth Group

  • Recent earnings reports showed a miss on EPS estimates, which could raise concerns about the company's short-term profitability.
  • Some analysts have downgraded their price targets, reflecting a more cautious outlook on the stock's future performance.
  • The company has a relatively high dividend payout ratio of 38.30%, which may limit its ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$326.22 billion
P/E Ratio
15.61
Consensus Rating
Hold
Consensus Price Target
$358.95 (-0.3% Downside)
Volume
13.47 million shares
Average Volume
13.19 million shares
Today's Range
$356.61
$368.00
50-Day Range
$237.40
$360.17
52-Week Range
$234.60
$630.73
Dividend Yield
2.45%
Novartis stock logo

5. Novartis NYSE:NVS

$132.41 +1.44 (+1.10%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$132.47 +0.06 (+0.05%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Market Capitalization
$279.66 billion
P/E Ratio
19.27
Consensus Rating
Hold
Consensus Price Target
$120.33 (-9.1% Downside)
Volume
1.42 million shares
Average Volume
1.32 million shares
Today's Range
$131.95
$133.37
50-Day Range
$113.55
$132.41
52-Week Range
$96.06
$133.37
Dividend Yield
1.96%
Novo Nordisk A/S stock logo

6. Novo Nordisk A/S NYSE:NVO

$59.68 +0.94 (+1.59%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$59.80 +0.12 (+0.21%)
As of 10/3/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent upgrades from multiple analysts, including a "buy" rating from HSBC, indicate strong confidence in the company's future performance.
  • The current stock price is around $58.82, reflecting a significant increase in trading volume, which may suggest growing investor interest.
  • Analysts have noted potential boosts from new programs, such as the Trump GLP-1 Pilot Program, which could enhance sales for Novo Nordisk's products.

Cons of Novo Nordisk A/S

  • Despite recent upgrades, some analysts have downgraded their ratings, indicating mixed sentiments about the stock's future performance.
  • The stock has experienced fluctuations, with a twelve-month high of $120.56 and a low of $45.05, suggesting volatility that could deter risk-averse investors.
  • Concerns about the company's debt-to-equity ratio of 0.52 may raise red flags for investors wary of financial leverage and its implications for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$266.25 billion
P/E Ratio
16.39
Consensus Rating
Moderate Buy
Consensus Price Target
$77.50 (+29.9% Upside)
Volume
15.33 million shares
Average Volume
15.88 million shares
Today's Range
$58.45
$60.10
50-Day Range
$45.31
$68.98
52-Week Range
$45.05
$120.56
Dividend Yield
1.38%
AstraZeneca stock logo

7. AstraZeneca NASDAQ:AZN

$85.31 +1.66 (+1.98%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$85.32 +0.02 (+0.02%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $76, which reflects a stable performance in the market.
  • AstraZeneca has shown significant growth in institutional investments, with several firms increasing their stakes recently, indicating strong confidence in the company's future.
  • The company has a solid market capitalization of approximately $236 billion, suggesting a robust financial position and potential for growth.

Cons of AstraZeneca

  • The stock has experienced fluctuations, with a recent trading volume lower than its average, which may indicate reduced investor interest.
  • AstraZeneca's debt-to-equity ratio is 0.55, which, while manageable, suggests that the company has a moderate level of debt that could impact financial flexibility.
  • Recent sales by institutional investors, such as HB Wealth Management reducing its stake by over 40%, may signal concerns about the company's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$264.58 billion
P/E Ratio
32.07
Consensus Rating
Moderate Buy
Consensus Price Target
$86.00 (+0.8% Upside)
Volume
5.87 million shares
Average Volume
4.77 million shares
Today's Range
$83.84
$85.50
50-Day Range
$71.83
$85.31
52-Week Range
$61.24
$85.50
Dividend Yield
1.18%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$134.49 +1.50 (+1.13%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$134.33 -0.16 (-0.12%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $131, which is near its 12-month high, indicating strong market performance and potential for further growth.
  • Abbott Laboratories has reported a significant year-over-year revenue increase of 7.4%, showcasing its ability to grow and adapt in the healthcare market.
  • The company has a solid net margin of over 32%, reflecting efficient operations and profitability, which can lead to higher returns for investors.

Cons of Abbott Laboratories

  • The price-to-earnings (P/E) ratio of 16.73, while reasonable, may indicate that the stock is not undervalued compared to its peers, which could limit upside potential.
  • Abbott Laboratories has a beta of 0.69, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Recent insider selling, including a significant transaction by the CFO, could raise concerns about the company's future performance and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$234.25 billion
P/E Ratio
16.85
Consensus Rating
Moderate Buy
Consensus Price Target
$145.39 (+8.1% Upside)
Volume
5.36 million shares
Average Volume
5.76 million shares
Today's Range
$132.79
$135.37
50-Day Range
$126.16
$136.82
52-Week Range
$110.86
$141.23
Dividend Yield
1.75%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$89.25 -0.26 (-0.29%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$89.70 +0.45 (+0.51%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $82, which is relatively stable compared to its twelve-month high of $114.60, indicating potential for growth.
  • Merck has a strong return on equity of over 41%, suggesting effective management and profitability, which can attract investors looking for solid performance.
  • The company recently reported earnings per share of $2.13, exceeding analysts' expectations, which reflects strong operational performance and can boost investor confidence.

Cons of Merck & Co., Inc.

  • Merck's revenue for the last quarter was slightly below analysts' expectations, which may raise concerns about future growth potential.
  • The company has received mixed ratings from analysts, with a consensus rating of "Hold," indicating uncertainty about its future performance.
  • Recent price target reductions by major analysts suggest a lack of confidence in short-term price appreciation, which could deter potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$222.78 billion
P/E Ratio
13.75
Consensus Rating
Hold
Consensus Price Target
$106.41 (+19.2% Upside)
Volume
12.97 million shares
Average Volume
14.21 million shares
Today's Range
$88.10
$90.70
50-Day Range
$77.70
$90.13
52-Week Range
$73.31
$111.58
Dividend Yield
3.63%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$543.88 +18.92 (+3.60%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$543.75 -0.13 (-0.02%)
As of 10/3/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $531.69, reflecting a strong market position and potential for growth.
  • The company reported a quarterly earnings per share (EPS) of $5.36, exceeding analysts' expectations, indicating robust financial performance.
  • Thermo Fisher Scientific Inc. has a solid revenue growth of 2.9% year-over-year, showcasing its ability to expand in the competitive life sciences sector.

Cons of Thermo Fisher Scientific

  • Insider selling has been notable, with executives selling over 30,000 shares recently, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, with a 52-week high of $620.00 and a low of $385.46, indicating potential volatility that could deter risk-averse investors.
  • Analysts have mixed ratings, with some maintaining a "hold" rating, suggesting uncertainty about the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$205.16 billion
P/E Ratio
31.46
Consensus Rating
Moderate Buy
Consensus Price Target
$585.37 (+7.6% Upside)
Volume
3.05 million shares
Average Volume
2.54 million shares
Today's Range
$525.36
$545.44
50-Day Range
$449.68
$543.88
52-Week Range
$385.46
$610.97
Dividend Yield
0.32%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$452.35 +9.34 (+2.11%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$454.50 +2.15 (+0.48%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $467, which reflects a strong position in the market and potential for growth.
  • Intuitive Surgical, Inc. reported a significant increase in quarterly revenue, up 21.4% year-over-year, indicating robust demand for its products.
  • The company has a high net margin of 28.51%, suggesting efficient operations and strong profitability.

Cons of Intuitive Surgical

  • The price-to-earnings (P/E) ratio is 61.26, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has occurred recently, with 45,224 shares sold, which could indicate a lack of confidence from those within the company.
  • The stock has experienced volatility, with a beta of 1.61, meaning it is more volatile than the market, which could pose risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$162.16 billion
P/E Ratio
63.09
Consensus Rating
Moderate Buy
Consensus Price Target
$594.19 (+31.4% Upside)
Volume
2.20 million shares
Average Volume
2.44 million shares
Today's Range
$443.49
$456.59
50-Day Range
$433.66
$500.51
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$297.89 +0.49 (+0.16%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$298.21 +0.32 (+0.11%)
As of 10/3/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has received multiple "outperform" and "overweight" ratings from analysts, indicating strong confidence in the company's future performance.
  • The current stock price is around $296, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Recent upgrades in price targets by analysts suggest a positive outlook, with some estimates reaching as high as $342, indicating potential for price appreciation.

Cons of Amgen

  • Despite positive ratings, there is an "underperform" rating from Bank of America, suggesting some analysts have concerns about the stock's performance relative to the market.
  • Insider selling activity, such as the recent sale of shares by a senior vice president, may raise red flags about the company's short-term prospects.
  • The average target price of $309.70 indicates limited upside potential from the current stock price, which may deter aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$160.37 billion
P/E Ratio
24.36
Consensus Rating
Hold
Consensus Price Target
$309.70 (+4.0% Upside)
Volume
2.52 million shares
Average Volume
2.81 million shares
Today's Range
$295.63
$301.54
50-Day Range
$271.18
$303.56
52-Week Range
$253.30
$335.88
Dividend Yield
3.20%
Pfizer stock logo

13. Pfizer NYSE:PFE

$27.36 +0.29 (+1.05%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$27.35 -0.01 (-0.05%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. recently reported strong quarterly earnings, with earnings per share (EPS) of $0.78, significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company achieved a revenue of approximately $14.65 billion for the quarter, reflecting a year-over-year growth of over 10%, showcasing its ability to expand its market presence.
  • Analysts have set a consensus target price of around $28.29 for Pfizer Inc., suggesting potential upside for investors based on current market evaluations.

Cons of Pfizer

  • Despite recent successes, the stock has received mixed ratings from analysts, with a significant number maintaining a "Hold" rating, indicating uncertainty about its future performance.
  • Recent downgrades from some analysts, including a shift from "Buy" to "Hold," may signal potential concerns about the stock's growth trajectory and market competitiveness.
  • Pfizer Inc. operates in a highly competitive biopharmaceutical market, which can lead to volatility in stock performance and uncertainty regarding future product success.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$155.61 billion
P/E Ratio
14.56
Consensus Rating
Hold
Consensus Price Target
$28.41 (+3.8% Upside)
Volume
70.44 million shares
Average Volume
60.20 million shares
Today's Range
$27.04
$27.69
50-Day Range
$23.27
$27.37
52-Week Range
$20.92
$30.43
Dividend Yield
6.28%
Danaher stock logo

14. Danaher NYSE:DHR

$215.05 +4.72 (+2.24%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$215.35 +0.30 (+0.14%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $211, reflecting a stable position in the market.
  • Danaher Co. has a solid dividend yield of 0.6%, providing a consistent income stream for investors.
  • The company has a low dividend payout ratio of 27.23%, indicating that it retains a significant portion of its earnings for growth and reinvestment.

Cons of Danaher

  • Despite positive ratings, some analysts have recently lowered their price targets, indicating potential concerns about future growth.
  • Insider selling activity, such as the recent sale of shares by a director, may raise questions about the company's short-term outlook.
  • The stock has a relatively low dividend yield compared to other investment opportunities, which may not attract income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$153.94 billion
P/E Ratio
45.75
Consensus Rating
Moderate Buy
Consensus Price Target
$245.91 (+14.4% Upside)
Volume
5.92 million shares
Average Volume
4.95 million shares
Today's Range
$210.22
$219.92
50-Day Range
$181.56
$215.05
52-Week Range
$171.00
$279.41
Dividend Yield
0.60%
Boston Scientific stock logo

15. Boston Scientific NYSE:BSX

$97.30 +1.08 (+1.12%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$97.86 +0.56 (+0.58%)
As of 10/3/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company reported a strong earnings per share (EPS) of $0.75 for the latest quarter, exceeding analyst expectations, which indicates robust financial performance.
  • Boston Scientific Co. has shown significant revenue growth, with a quarterly revenue increase of approximately 22.8% compared to the same period last year, suggesting strong demand for its medical devices.
  • Institutional investors hold a substantial portion of the company’s stock, with 89.07% owned by such entities, reflecting confidence in the company's future prospects.

Cons of Boston Scientific

  • Insider selling has been observed, with corporate insiders selling a significant number of shares recently, which may raise concerns about their confidence in the company's future.
  • The company has a relatively low insider ownership of only 0.50%, which could indicate a lack of alignment between management and shareholders.
  • Despite strong revenue growth, the company faces intense competition in the medical device sector, which could impact future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$144.20 billion
P/E Ratio
57.91
Consensus Rating
Buy
Consensus Price Target
$120.79 (+24.1% Upside)
Volume
10.77 million shares
Average Volume
11.93 million shares
Today's Range
$96.10
$98.48
50-Day Range
$95.78
$108.15
52-Week Range
$80.64
$109.50
Dividend Yield
N/A
Stryker stock logo

16. Stryker NYSE:SYK

$370.59 +4.19 (+1.14%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$369.14 -1.44 (-0.39%)
As of 10/3/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $406, reflecting a strong performance in the medical technology sector.
  • Stryker Co. has a solid annual dividend yield of 0.9%, providing a steady income stream for investors.
  • The company reported a significant year-over-year revenue increase of 11.1%, indicating robust growth potential.

Cons of Stryker

  • The stock has a high PE ratio of 48.88, which may indicate that it is overvalued compared to its earnings.
  • Despite strong revenue growth, the company faces increasing competition in the medical technology market, which could impact future performance.
  • The beta of 0.93 suggests that the stock is less volatile than the market, but it may also limit potential high returns during market upswings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$141.64 billion
P/E Ratio
49.08
Consensus Rating
Moderate Buy
Consensus Price Target
$430.33 (+16.1% Upside)
Volume
1.08 million shares
Average Volume
1.43 million shares
Today's Range
$366.81
$373.22
50-Day Range
$364.07
$400.81
52-Week Range
$329.16
$406.19
Dividend Yield
0.91%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$112.69 +2.13 (+1.93%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$112.84 +0.15 (+0.13%)
As of 10/3/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $113.57, which reflects a stable valuation in the biopharmaceutical sector.
  • Gilead Sciences, Inc. has reported strong quarterly earnings, exceeding consensus estimates, indicating robust financial health and operational efficiency.
  • The company has a solid market capitalization of approximately $137.73 billion, suggesting a strong position in the market and potential for growth.

Cons of Gilead Sciences

  • Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future prospects.
  • The company has a debt-to-equity ratio of 1.13, indicating a reliance on debt financing, which could pose risks in a rising interest rate environment.
  • Despite recent revenue growth, the overall market for biopharmaceuticals can be volatile, influenced by regulatory changes and competitive pressures.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.83 billion
P/E Ratio
22.45
Consensus Rating
Moderate Buy
Consensus Price Target
$117.17 (+4.0% Upside)
Volume
8.09 million shares
Average Volume
8.11 million shares
Today's Range
$109.66
$113.59
50-Day Range
$110.28
$120.47
52-Week Range
$83.98
$121.83
Dividend Yield
2.80%
Medtronic stock logo

18. Medtronic NYSE:MDT

$97.63 +2.15 (+2.25%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$96.54 -1.09 (-1.12%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $100, reflecting a positive outlook from analysts who have recently increased their price targets for the stock.
  • Medtronic plc has a strong dividend payout ratio of 78.24%, indicating a commitment to returning value to shareholders through regular dividend payments.
  • Recent upgrades from multiple analysts, including a "neutral" rating from UBS Group and an "overweight" rating from Wells Fargo, suggest growing confidence in the company's performance.

Cons of Medtronic

  • The high dividend payout ratio of 78.24% may raise concerns about the sustainability of dividends, especially if the company faces financial challenges.
  • Despite positive analyst ratings, the stock has a consensus rating of "Moderate Buy," which may indicate a lack of overwhelming confidence in the stock's potential for significant growth.
  • Recent changes in institutional holdings, while generally positive, can also indicate volatility as large investors adjust their positions based on market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$125.32 billion
P/E Ratio
26.90
Consensus Rating
Moderate Buy
Consensus Price Target
$100.94 (+3.4% Upside)
Volume
8.57 million shares
Average Volume
7.56 million shares
Today's Range
$95.38
$97.94
50-Day Range
$89.31
$97.63
52-Week Range
$79.29
$97.94
Dividend Yield
2.91%
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$50.90 +0.76 (+1.52%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$50.79 -0.11 (-0.22%)
As of 10/3/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Recent upgrades from multiple analysts, including a raise from Morgan Stanley to an "overweight" rating, indicate growing confidence in the company's performance.
  • The stock is currently priced around $50, which is below the consensus target price of approximately $62.67, suggesting potential for price appreciation.
  • Sanofi reported a significant revenue of $11.34 billion in its latest quarterly earnings, exceeding analysts' expectations, which reflects strong operational performance.

Cons of Sanofi

  • Despite strong revenue, Sanofi's earnings per share fell short of analysts' expectations, which may raise concerns about future profitability.
  • The stock has experienced fluctuations, with a twelve-month low of around $44.62, indicating potential volatility that could deter risk-averse investors.
  • Sanofi's net margin of 21.47% suggests that while the company is profitable, there may be pressures on profitability that could affect future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$124.99 billion
P/E Ratio
12.24
Consensus Rating
Buy
Consensus Price Target
$62.67 (+23.1% Upside)
Volume
3.73 million shares
Average Volume
4.16 million shares
Today's Range
$50.33
$51.05
50-Day Range
$45.07
$51.35
52-Week Range
$44.62
$60.12
Dividend Yield
3.14%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$403.30 -5.55 (-1.36%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$403.82 +0.51 (+0.13%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company recently reported strong earnings, with an EPS of $4.52, exceeding expectations, indicating robust financial health and operational efficiency.
  • Vertex Pharmaceuticals Incorporated has shown significant revenue growth, with a year-over-year increase of 11.3%, suggesting a strong demand for its products.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with an average price target of approximately $493.81, indicating potential for price appreciation.

Cons of Vertex Pharmaceuticals

  • Despite recent growth, the stock has experienced volatility, with a 52-week range showing a low of $362.50 and a high of $519.88, indicating potential risks associated with price fluctuations.
  • Some analysts have downgraded their price targets, suggesting a cautious outlook on the stock's short-term performance.
  • The company faces competition in the biotechnology sector, which could impact its market share and profitability in the future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$103.40 billion
P/E Ratio
28.83
Consensus Rating
Moderate Buy
Consensus Price Target
$493.81 (+22.4% Upside)
Volume
1.32 million shares
Average Volume
1.74 million shares
Today's Range
$403.04
$411.91
50-Day Range
$366.54
$472.27
52-Week Range
$362.50
$519.88
Dividend Yield
N/A
HCA Healthcare stock logo

21. HCA Healthcare NYSE:HCA

$429.52 +2.83 (+0.66%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$429.42 -0.10 (-0.02%)
As of 10/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The company recently reported strong earnings, with an EPS of $6.84, exceeding analysts' expectations, indicating robust financial performance.
  • HCA Healthcare, Inc. has shown a significant year-over-year revenue growth of 6.4%, suggesting a positive trend in business operations.
  • The current stock price is around $408, reflecting a solid market position and investor confidence in the company's future prospects.

Cons of HCA Healthcare

  • The company has a notably high negative return on equity, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Insider selling activity has been observed, with an executive recently reducing their stake by over 10%, which could signal a lack of confidence in the company's short-term performance.
  • HCA Healthcare, Inc. has a high debt-to-equity ratio, indicating that the company relies heavily on debt financing, which can be risky in volatile market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.51 billion
P/E Ratio
18.05
Consensus Rating
Moderate Buy
Consensus Price Target
$407.75 (-5.1% Downside)
Volume
988,386 shares
Average Volume
1.31 million shares
Today's Range
$425.81
$432.36
50-Day Range
$340.31
$429.52
52-Week Range
$289.98
$432.36
Dividend Yield
0.67%
CVS Health stock logo

22. CVS Health NYSE:CVS

$77.51 +0.06 (+0.08%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$77.49 -0.02 (-0.03%)
As of 10/3/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $78, which is supported by a consensus target price of approximately $78.25, indicating potential for growth.
  • CVS Health Co. recently reported strong quarterly earnings, with earnings per share (EPS) of $1.81, surpassing estimates and reflecting solid financial performance.
  • The company has a diverse business model, operating in Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, which can provide stability and growth opportunities.

Cons of CVS Health

  • The company has a relatively high debt-to-equity ratio of 0.74, which may indicate increased financial risk and reliance on borrowed funds.
  • CVS Health Co. has a current ratio of 0.80, suggesting potential liquidity issues, as it may struggle to cover short-term liabilities with its current assets.
  • Recent earnings showed a slight decline in EPS compared to the same quarter last year, which could raise concerns about growth sustainability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$98.28 billion
P/E Ratio
21.65
Consensus Rating
Moderate Buy
Consensus Price Target
$78.25 (+1.0% Upside)
Volume
7.08 million shares
Average Volume
7.79 million shares
Today's Range
$77.08
$79.20
50-Day Range
$59.65
$77.51
52-Week Range
$43.56
$79.20
Dividend Yield
3.43%
Bristol Myers Squibb stock logo

23. Bristol Myers Squibb NYSE:BMY

$45.39 -0.34 (-0.75%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$45.49 +0.10 (+0.22%)
As of 10/3/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company recently reported strong quarterly earnings, with earnings per share (EPS) of $1.46, significantly exceeding analysts' expectations, indicating robust financial performance.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including leading treatments for various cancers and other serious diseases, which positions it well in the healthcare market.
  • The current stock price is around $50, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.

Cons of Bristol Myers Squibb

  • The company has a high dividend payout ratio of 100%, which means it is returning all of its earnings to shareholders, potentially limiting funds available for reinvestment in growth opportunities.
  • Despite recent revenue growth, the company faces intense competition in the biopharmaceutical industry, which could impact its market share and profitability.
  • Recent earnings were only slightly up year-over-year, indicating that growth may be slowing, which could be a concern for long-term investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.51 billion
P/E Ratio
18.30
Consensus Rating
Hold
Consensus Price Target
$56.38 (+24.2% Upside)
Volume
17.89 million shares
Average Volume
17.06 million shares
Today's Range
$44.66
$46.18
50-Day Range
$43.37
$48.45
52-Week Range
$42.96
$63.33
Dividend Yield
5.46%
McKesson stock logo

24. McKesson NYSE:MCK

$738.00 -20.70 (-2.73%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$741.52 +3.52 (+0.48%)
As of 10/3/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $720, reflecting a strong market position and investor confidence in the company's future growth.
  • McKesson Co. recently reported a significant year-over-year revenue increase of 23.4%, indicating robust business performance and demand for its healthcare services.
  • The company has a solid market capitalization of approximately $94.63 billion, showcasing its stability and potential for long-term growth.

Cons of McKesson

  • Insider selling has been notable, with corporate insiders selling over 43,000 shares recently, which may raise concerns about their confidence in the company's future performance.
  • The company reported a negative return on equity of 196.66%, indicating that it is currently not generating profit relative to shareholder equity, which could be a red flag for potential investors.
  • Despite revenue growth, the earnings per share (EPS) missed analysts' expectations, which could signal challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$91.80 billion
P/E Ratio
29.43
Consensus Rating
Moderate Buy
Consensus Price Target
$829.08 (+12.3% Upside)
Volume
1.09 million shares
Average Volume
763,633 shares
Today's Range
$730.04
$762.16
50-Day Range
$658.78
$772.61
52-Week Range
$480.39
$776.14
Dividend Yield
0.44%
GSK stock logo

25. GSK NYSE:GSK

$43.30 -0.39 (-0.89%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$43.38 +0.08 (+0.18%)
As of 10/3/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $40.81, which reflects a stable market position and potential for growth.
  • GSK plc reported strong quarterly earnings, with earnings per share (EPS) of $1.23, exceeding analysts' expectations, indicating robust financial health.
  • The company has shown a year-over-year revenue increase of 1.3%, suggesting consistent demand for its products.

Cons of GSK

  • The stock has experienced fluctuations, with a 52-week high of $43.62 and a low of $31.72, indicating potential volatility.
  • GSK plc has a debt-to-equity ratio of 1.07, which suggests that the company has a significant amount of debt compared to its equity, potentially increasing financial risk.
  • Despite recent earnings growth, the price-to-earnings (P/E) ratio of around 18.89 may indicate that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.19 billion
P/E Ratio
20.05
Consensus Rating
Reduce
Consensus Price Target
$37.38 (-13.7% Downside)
Volume
13.11 million shares
Average Volume
5.52 million shares
Today's Range
$43.04
$44.26
50-Day Range
$36.79
$45.52
52-Week Range
$31.72
$45.59
Dividend Yield
3.88%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$311.24 +14.26 (+4.80%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$311.02 -0.22 (-0.07%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $300, which may present a buying opportunity for investors looking for value in the insurance sector.
  • The company has a solid annualized dividend of $6.04, providing a yield of 2.1%, which can be attractive for income-focused investors.
  • The dividend payout ratio is currently at 32.97%, indicating that the company retains a significant portion of its earnings for growth while still rewarding shareholders.

Cons of Cigna Group

  • Insider ownership is relatively low at 0.70%, which may raise concerns about alignment between management and shareholder interests.
  • One insider recently sold 28,526 shares, representing a 52.66% decrease in their ownership, which could signal a lack of confidence in the company's short-term performance.
  • The company’s earnings per share (EPS) guidance for FY 2025 is set at 29.600, which is slightly lower than the current year’s forecast, indicating potential slowing growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$83.01 billion
P/E Ratio
16.99
Consensus Rating
Moderate Buy
Consensus Price Target
$371.81 (+19.5% Upside)
Volume
2.84 million shares
Average Volume
1.45 million shares
Today's Range
$295.95
$315.47
50-Day Range
$262.26
$311.24
52-Week Range
$256.89
$358.88
Dividend Yield
1.94%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$351.11 +10.87 (+3.20%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$352.75 +1.64 (+0.47%)
As of 10/3/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$78.92 billion
P/E Ratio
14.94
Consensus Rating
Moderate Buy
Consensus Price Target
$411.06 (+17.1% Upside)
Volume
2.68 million shares
Average Volume
2.00 million shares
Today's Range
$341.09
$357.00
50-Day Range
$274.10
$351.11
52-Week Range
$273.71
$510.24
Dividend Yield
1.95%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$146.45 -0.04 (-0.02%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$146.00 -0.45 (-0.31%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $143, which is relatively stable compared to its 52-week high of approximately $197, indicating potential for growth.
  • Zoetis Inc. reported strong quarterly earnings, with earnings per share of $1.76, surpassing analysts' expectations, which reflects robust financial health.
  • The company has a high return on equity of 56.90%, suggesting effective management and profitability, which can attract investors looking for solid returns.

Cons of Zoetis

  • The stock has experienced fluctuations, with a recent decline of about 0.4%, which may indicate volatility and risk for investors.
  • Analysts have issued mixed ratings, with some downgrading their outlook, which could signal uncertainty about the company's future performance.
  • The company's debt-to-equity ratio is 1.05, suggesting a moderate level of debt, which could be a concern for investors wary of financial leverage.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$64.89 billion
P/E Ratio
25.21
Consensus Rating
Moderate Buy
Consensus Price Target
$200.88 (+37.2% Upside)
Volume
2.57 million shares
Average Volume
3.02 million shares
Today's Range
$146.25
$148.79
50-Day Range
$141.03
$156.69
52-Week Range
$139.34
$196.55
Dividend Yield
1.37%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$600.00 0.00 (0.00%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$604.24 +4.24 (+0.71%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • Regeneron Pharmaceuticals, Inc. has a solid revenue growth trajectory, with quarterly revenue up compared to the same period last year, showcasing its ability to expand its market presence.
  • The current stock price is around $567.89, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced a decline of about 4.7% recently, which may indicate short-term volatility and investor uncertainty.
  • Some analysts have downgraded their ratings on the stock, reflecting mixed sentiments in the market regarding its future performance.
  • The company operates in a highly competitive biopharmaceutical industry, which can pose risks to its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.59 billion
P/E Ratio
15.12
Consensus Rating
Moderate Buy
Consensus Price Target
$817.67 (+36.3% Upside)
Volume
1.15 million shares
Average Volume
1.13 million shares
Today's Range
$599.87
$618.01
50-Day Range
$545.46
$600.00
52-Week Range
$476.49
$1,024.36
Dividend Yield
0.59%
Alnylam Pharmaceuticals stock logo

30. Alnylam Pharmaceuticals NASDAQ:ALNY

$456.35 -4.64 (-1.01%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$451.82 -4.53 (-0.99%)
As of 10/3/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Alnylam Pharmaceuticals, Inc. has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent ratings include a "buy" from Bank of America and Citigroup, with price targets significantly above the current stock price.
  • The current stock price is around $449, reflecting a robust market capitalization of approximately $58.93 billion, which suggests a strong position in the biotech sector.
  • Twenty-four analysts have rated the stock with a "Buy" rating, showcasing widespread optimism about the company's growth potential and product pipeline.

Cons of Alnylam Pharmaceuticals

  • The company has a high debt-to-equity ratio of 4.10, indicating that it relies heavily on debt financing, which could pose risks if market conditions change.
  • Despite positive analyst ratings, the stock has experienced fluctuations, and the price-to-earnings ratio is negative, suggesting that the company is not currently profitable.
  • Insider sales have totaled over 75,000 shares recently, which could be interpreted as a lack of confidence in the stock's future performance by those who are most familiar with the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$59.82 billion
P/E Ratio
-184.76
Consensus Rating
Moderate Buy
Consensus Price Target
$439.58 (-3.7% Downside)
Volume
969,084 shares
Average Volume
1.17 million shares
Today's Range
$448.47
$465.01
50-Day Range
$324.79
$482.13
52-Week Range
$205.87
$484.21
Dividend Yield
N/A
Cencora stock logo

31. Cencora NYSE:COR

$302.54 -6.03 (-1.95%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$297.94 -4.60 (-1.52%)
As of 10/3/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $301.95, reflecting a strong market position and potential for growth.
  • Recent earnings reports show that Cencora, Inc. exceeded analysts' expectations, indicating robust financial health and operational efficiency.
  • The company has a solid dividend yield of approximately 0.7%, providing a steady income stream for investors.

Cons of Cencora

  • The company has a high debt-to-equity ratio, which may indicate financial risk and could affect its ability to manage debt obligations.
  • Despite recent growth, the net margin is relatively low, suggesting that profitability could be a concern in the long term.
  • Market volatility could impact stock performance, especially given the company's beta of 0.62, which indicates lower volatility compared to the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$58.70 billion
P/E Ratio
31.13
Consensus Rating
Moderate Buy
Consensus Price Target
$311.25 (+2.9% Upside)
Volume
1.25 million shares
Average Volume
1.82 million shares
Today's Range
$296.08
$308.54
50-Day Range
$278.18
$312.10
52-Week Range
$218.65
$315.23
Dividend Yield
0.73%
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$193.67 +2.07 (+1.08%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$192.75 -0.92 (-0.48%)
As of 10/3/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $180, which may present a buying opportunity for investors looking for value in the medical supplies sector.
  • Becton, Dickinson and Company reported strong earnings, with earnings per share exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • The company has shown a year-over-year revenue increase of over 10%, suggesting growth potential and a solid market position in the healthcare industry.

Cons of Becton, Dickinson and Company

  • The stock has experienced a decrease in insider ownership, with recent sales indicating a potential lack of confidence from executives, which could raise concerns for investors.
  • The price-to-earnings ratio of 33.64 suggests that the stock may be overvalued compared to its earnings, which could deter value investors.
  • Despite revenue growth, the company's net margin of 7.51% may indicate challenges in maintaining profitability, which could affect future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.49 billion
P/E Ratio
34.83
Consensus Rating
Hold
Consensus Price Target
$205.40 (+6.1% Upside)
Volume
977,135 shares
Average Volume
1.53 million shares
Today's Range
$191.45
$195.33
50-Day Range
$172.50
$199.50
52-Week Range
$163.33
$251.99
Dividend Yield
2.15%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$631.19 -2.65 (-0.42%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$629.46 -1.73 (-0.27%)
As of 10/3/2025 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $627, reflecting strong market interest and potential for growth.
  • IDEXX Laboratories, Inc. reported a significant earnings per share (EPS) of $3.63 for the latest quarter, surpassing analysts' expectations, indicating robust financial performance.
  • The company has a high return on equity of 64.42%, suggesting effective management and strong profitability relative to shareholder equity.

Cons of IDEXX Laboratories

  • The stock has a relatively high price-to-earnings (P/E) ratio of 52.22, which may indicate that it is overvalued compared to its earnings.
  • Despite strong performance, the company's beta of 1.56 suggests higher volatility compared to the market, which could lead to greater risk for investors.
  • Recent selling by institutional investors, such as the State of Alaska Department of Revenue reducing its holdings by 5.8%, may signal a lack of confidence among some large stakeholders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.50 billion
P/E Ratio
52.56
Consensus Rating
Moderate Buy
Consensus Price Target
$656.50 (+4.0% Upside)
Volume
338,549 shares
Average Volume
427,159 shares
Today's Range
$627.97
$642.25
50-Day Range
$534.31
$682.78
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
argenex stock logo

34. argenex NASDAQ:ARGX

$800.00 +8.41 (+1.06%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$800.26 +0.26 (+0.03%)
As of 10/3/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $350, reflecting strong market interest in the company's innovative therapies.
  • Argentx SE's lead product candidate, efgartigimod, has shown promising results in treating various autoimmune diseases, which could lead to significant revenue growth.
  • The company has established strategic partnerships with major firms like AbbVie and Zai Lab, enhancing its research capabilities and market reach.

Cons of argenex

  • The biotechnology sector is highly volatile, and argenx SE's stock may experience significant price fluctuations based on clinical trial results and regulatory approvals.
  • Competition in the autoimmune disease treatment market is intense, with many companies developing similar therapies, which could impact argenx SE's market share.
  • Investors may face uncertainty regarding the long-term profitability of argenx SE, as the success of its therapies is contingent on ongoing clinical trials and market acceptance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.96 billion
P/E Ratio
41.03
Consensus Rating
Buy
Consensus Price Target
$802.90 (+0.4% Upside)
Volume
353,762 shares
Average Volume
370,305 shares
Today's Range
$790.85
$803.74
50-Day Range
$595.19
$800.00
52-Week Range
$510.05
$803.74
Dividend Yield
N/A
Veeva Systems stock logo

35. Veeva Systems NYSE:VEEV

$296.47 -4.32 (-1.43%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$296.20 -0.27 (-0.09%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $280, reflecting a recent increase of 0.8%, which may indicate positive market sentiment.
  • Analysts have recently upgraded their ratings on Veeva Systems Inc., with several firms raising their price targets significantly, suggesting strong future growth potential.
  • Veeva Systems Inc. has a robust market capitalization of approximately $45.91 billion, indicating a strong position in the cloud-based software sector for life sciences.

Cons of Veeva Systems

  • Insider selling has occurred recently, with a senior vice president selling 720 shares, which could raise concerns about the company's short-term outlook.
  • The stock has a high price-to-earnings (P/E) ratio of 57.51, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite recent upgrades, some analysts still maintain a "Hold" rating, suggesting that not all market participants are convinced of the stock's upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.56 billion
P/E Ratio
60.88
Consensus Rating
Moderate Buy
Consensus Price Target
$303.67 (+2.4% Upside)
Volume
1.85 million shares
Average Volume
1.30 million shares
Today's Range
$294.18
$302.00
50-Day Range
$268.85
$300.43
52-Week Range
$200.30
$302.00
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

36. Takeda Pharmaceutical NYSE:TAK

$14.62 +0.18 (+1.21%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$14.44 -0.17 (-1.16%)
As of 10/3/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $15.59, which reflects a recent increase and indicates positive market sentiment towards the company.
  • Takeda Pharmaceutical Company Limited recently reached a new 52-week high, showcasing strong performance and investor confidence.
  • The company reported earnings per share (EPS) of $0.52, exceeding analysts' expectations, which suggests effective management and operational efficiency.

Cons of Takeda Pharmaceutical

  • Recent downgrades by analysts, including a shift from a "hold" to a "strong sell" rating, may indicate underlying concerns about the company's future performance.
  • The company has a relatively high price-to-earnings (P/E) ratio of around 51.48, which could suggest that the stock is overvalued compared to its earnings potential.
  • Takeda Pharmaceutical Company Limited's revenue for the last quarter fell short of expectations, which may raise concerns about its growth trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.46 billion
P/E Ratio
48.72
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
2.67 million shares
Average Volume
2.96 million shares
Today's Range
$14.45
$14.62
50-Day Range
$13.60
$15.50
52-Week Range
$12.80
$15.69
Dividend Yield
3.78%
Edwards Lifesciences stock logo

37. Edwards Lifesciences NYSE:EW

$77.03 +0.38 (+0.49%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$77.07 +0.04 (+0.06%)
As of 10/3/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • Recent upgrades from multiple analysts, including a "strong-buy" rating from William Blair, indicate strong confidence in the company's future performance.
  • The current stock price is around $76, which may present a buying opportunity for investors looking for potential growth.
  • Edwards Lifesciences Co. has a solid market capitalization of approximately $45 billion, suggesting a stable financial foundation.

Cons of Edwards Lifesciences

  • Despite recent upgrades, the stock has shown a slight decline of about 1.7%, which may raise concerns about short-term performance.
  • Insider selling activity, including significant sales by executives, could signal a lack of confidence in the stock's near-term prospects.
  • The company has a relatively high price-to-earnings ratio compared to industry averages, which may indicate that the stock is overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.25 billion
P/E Ratio
11.08
Consensus Rating
Moderate Buy
Consensus Price Target
$86.61 (+12.4% Upside)
Volume
4.62 million shares
Average Volume
4.74 million shares
Today's Range
$76.50
$77.97
50-Day Range
$73.80
$81.76
52-Week Range
$64.00
$83.00
Dividend Yield
N/A
ResMed stock logo

38. ResMed NYSE:RMD

$278.48 +1.84 (+0.66%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$278.58 +0.10 (+0.04%)
As of 10/3/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. has received multiple upgrades from analysts, with a consensus rating of "Moderate Buy" and a price target of approximately $294.20, indicating strong potential for price appreciation.
  • The current stock price is around $287, which reflects a solid position in the market and suggests that the stock may be undervalued compared to its projected price target.
  • Insider trading activity shows that corporate insiders have sold shares recently, which can indicate confidence in the company's future performance, as they may be reallocating their investments rather than signaling a lack of faith in the company.

Cons of ResMed

  • Insider ownership is relatively low at 0.71%, which may suggest a lack of alignment between management and shareholders, potentially leading to decisions that do not prioritize shareholder value.
  • Recent insider sales, totaling over 18,000 shares, could raise concerns among investors about the company's short-term outlook, as significant sales by insiders may indicate they expect the stock price to decline.
  • The healthcare market is highly competitive, and ResMed Inc. faces challenges from other companies offering similar products, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.79 billion
P/E Ratio
29.28
Consensus Rating
Moderate Buy
Consensus Price Target
$294.20 (+5.6% Upside)
Volume
590,798 shares
Average Volume
909,613 shares
Today's Range
$277.24
$281.50
50-Day Range
$267.62
$293.48
52-Week Range
$199.92
$293.81
Dividend Yield
0.86%
Agilent Technologies stock logo

39. Agilent Technologies NYSE:A

$141.91 +3.21 (+2.31%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$139.52 -2.38 (-1.68%)
As of 10/3/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $126, reflecting a stable position in the market.
  • Recent institutional investments, including a $485,000 stake from NorthCrest Asset Management LLC, indicate strong confidence in the company's future performance.
  • Analysts have a consensus rating of "Moderate Buy" for Agilent Technologies, Inc., suggesting positive expectations for growth.

Cons of Agilent Technologies

  • Despite positive analyst ratings, some firms have issued lower target prices, such as UBS Group reducing their estimate from $150 to $130, which may indicate caution in the market.
  • The stock has experienced fluctuations, with a 12-month high of $153.84 and a low of $96.43, suggesting volatility that could be a concern for risk-averse investors.
  • While institutional interest is growing, the overall market sentiment can shift quickly, and any negative news could impact stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.15 billion
P/E Ratio
33.31
Consensus Rating
Hold
Consensus Price Target
$142.17 (+0.2% Upside)
Volume
2.35 million shares
Average Volume
1.81 million shares
Today's Range
$138.86
$143.09
50-Day Range
$113.32
$141.91
52-Week Range
$96.43
$153.84
Dividend Yield
0.70%
Haleon stock logo

40. Haleon NYSE:HLN

$8.94 +0.06 (+0.62%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$9.01 +0.07 (+0.84%)
As of 10/3/2025 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The company has recently increased its semi-annual dividend to $0.0555, reflecting a strong commitment to returning value to shareholders. This increase from the previous dividend indicates positive financial health and growth potential.
  • Haleon plc has a market capitalization of approximately $43.35 billion, suggesting a stable and significant presence in the consumer healthcare market, which can be attractive for long-term investors.
  • With a current price-to-earnings (P/E) ratio of around 24.83, the stock may be considered reasonably valued compared to its earnings, which can indicate potential for future growth.

Cons of Haleon

  • The PEG ratio of 2.90 suggests that the stock may be overvalued relative to its earnings growth, which could deter value-focused investors.
  • Analysts have mixed ratings, with some recent downgrades, including a reduction from "overweight" to "equal weight" by Barclays, indicating potential concerns about the stock's performance.
  • The beta of 0.23 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.98 billion
P/E Ratio
22.91
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+37.9% Upside)
Volume
7.89 million shares
Average Volume
9.31 million shares
Today's Range
$8.84
$8.98
50-Day Range
$8.74
$9.91
52-Week Range
$8.71
$11.42
Dividend Yield
1.28%
Alcon stock logo

41. Alcon NYSE:ALC

$77.34 +2.24 (+2.98%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$76.74 -0.61 (-0.79%)
As of 10/3/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that may attract investors.
  • The company has a significant institutional ownership percentage, suggesting confidence from large investors in its future prospects.

Cons of Alcon

  • The average daily volume has decreased, which may indicate reduced trading interest and liquidity concerns.
  • There has been a notable month-to-month change in shares shorted, suggesting some volatility in investor sentiment.
  • Despite a positive performance, the overall market conditions can still impact Alcon Inc.'s stock negatively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.17 billion
P/E Ratio
35.97
Consensus Rating
Moderate Buy
Consensus Price Target
$95.50 (+23.5% Upside)
Volume
2.38 million shares
Average Volume
1.98 million shares
Today's Range
$75.51
$77.50
50-Day Range
$73.32
$91.38
52-Week Range
$73.21
$99.20
Dividend Yield
N/A
BeOne Medicines stock logo

42. BeOne Medicines NASDAQ:ONC

$343.87 -1.30 (-0.38%)
As of 10/3/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$37.69 billion
P/E Ratio
-198.77
Consensus Rating
Moderate Buy
Consensus Price Target
$336.30 (-2.2% Downside)
Volume
163,179 shares
Average Volume
307,143 shares
Today's Range
$334.53
$347.09
50-Day Range
$288.10
$351.13
52-Week Range
$170.99
$355.30
Dividend Yield
N/A
Cardinal Health stock logo

43. Cardinal Health NYSE:CAH

$154.50 -3.96 (-2.50%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$154.34 -0.15 (-0.10%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $152, which is significantly higher than its 12-month low of $106.54, indicating a potential recovery and growth trend.
  • Cardinal Health, Inc. recently reported quarterly earnings that exceeded analysts' expectations, showcasing its ability to generate profits effectively.
  • The company has a positive revenue growth of 0.5% year-over-year, suggesting stability and resilience in its business operations.

Cons of Cardinal Health

  • Cardinal Health, Inc. has a negative return on equity of 74.45%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • Insider trading activity shows a significant decrease in ownership, with insiders selling over 271,000 shares, which could indicate a lack of confidence in the company's future performance.
  • The company’s revenue for the latest quarter fell short of analyst estimates, which may suggest challenges in meeting market expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.70 billion
P/E Ratio
23.95
Consensus Rating
Moderate Buy
Consensus Price Target
$165.93 (+7.4% Upside)
Volume
6.61 million shares
Average Volume
2.43 million shares
Today's Range
$150.77
$159.24
50-Day Range
$146.18
$158.64
52-Week Range
$106.98
$168.44
Dividend Yield
1.32%
IQVIA stock logo

44. IQVIA NYSE:IQV

$206.84 +2.50 (+1.22%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$206.65 -0.19 (-0.09%)
As of 10/3/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $188, which reflects a strong performance in the market and may indicate potential for growth.
  • Recent earnings results showed a positive trend, with earnings per share surpassing estimates, suggesting strong financial health and operational efficiency.
  • Analysts have a favorable outlook, with many rating the stock as a "buy" and setting price targets significantly above the current price, indicating potential upside.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio, which may indicate increased financial risk and could affect its ability to invest in growth opportunities.
  • Insider selling activity has been noted, with significant shares sold recently, which could raise concerns about the confidence of insiders in the company's future performance.
  • Despite positive earnings, the stock's price-to-earnings (P/E) ratio is relatively high, suggesting that the stock may be overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.13 billion
P/E Ratio
29.93
Consensus Rating
Moderate Buy
Consensus Price Target
$230.32 (+11.3% Upside)
Volume
1.73 million shares
Average Volume
1.30 million shares
Today's Range
$204.11
$209.48
50-Day Range
$176.72
$206.84
52-Week Range
$134.65
$237.34
Dividend Yield
N/A
GE HealthCare Technologies stock logo

45. GE HealthCare Technologies NASDAQ:GEHC

$76.56 -0.26 (-0.34%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$76.22 -0.34 (-0.44%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The current stock price is around $74.77, which may present a buying opportunity for investors looking for growth in the healthcare technology sector.
  • Recent earnings reports show that GE HealthCare Technologies Inc. exceeded revenue expectations, generating $5 billion, indicating strong demand for its products and services.
  • The company has a solid net margin of 11.22% and a return on equity of 23.93%, suggesting efficient management and profitability.

Cons of GE HealthCare Technologies

  • Despite recent positive earnings, the stock has seen fluctuations, and the current price is down slightly from its 52-week high of $94.80, which may indicate volatility.
  • The company has a debt-to-equity ratio of 0.85, which, while manageable, suggests that it has a significant amount of debt relative to its equity, potentially increasing financial risk.
  • Recent downgrades from some analysts, such as a shift from a "buy" to a "hold" rating, may signal caution regarding the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.95 billion
P/E Ratio
15.69
Consensus Rating
Moderate Buy
Consensus Price Target
$86.89 (+13.5% Upside)
Volume
2.70 million shares
Average Volume
3.71 million shares
Today's Range
$76.43
$77.95
50-Day Range
$69.85
$78.71
52-Week Range
$57.65
$94.80
Dividend Yield
0.18%
Humana stock logo

46. Humana NYSE:HUM

$284.00 +27.38 (+10.67%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$283.75 -0.25 (-0.09%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $258, which reflects a significant market presence and potential for growth.
  • Humana Inc. has shown a strong revenue increase of approximately 9.6% year-over-year, indicating robust business performance.
  • Analysts have recently upgraded their price targets for Humana, with some suggesting a target as high as $341, which could signal potential upside for investors.

Cons of Humana

  • The stock has experienced volatility, with a recent drop of about 4.7%, which may concern risk-averse investors.
  • Humana's earnings per share recently missed consensus estimates, which could indicate potential challenges in meeting growth expectations.
  • Despite positive revenue growth, the company's net margin is relatively low at 1.28%, which may raise concerns about profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.12 billion
P/E Ratio
21.80
Consensus Rating
Hold
Consensus Price Target
$291.21 (+2.5% Upside)
Volume
4.47 million shares
Average Volume
2.31 million shares
Today's Range
$255.01
$287.51
50-Day Range
$231.25
$312.22
52-Week Range
$206.87
$315.35
Dividend Yield
1.25%
Insmed stock logo

47. Insmed NASDAQ:INSM

$157.16 +4.36 (+2.85%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$157.98 +0.82 (+0.52%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$33.22 billion
P/E Ratio
-27.52
Consensus Rating
Moderate Buy
Consensus Price Target
$149.06 (-5.2% Downside)
Volume
3.49 million shares
Average Volume
2.12 million shares
Today's Range
$151.77
$158.19
50-Day Range
$101.75
$157.16
52-Week Range
$60.40
$158.19
Dividend Yield
N/A
Mettler-Toledo International stock logo

48. Mettler-Toledo International NYSE:MTD

$1,314.48 +13.94 (+1.07%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$1,310.15 -4.33 (-0.33%)
As of 10/3/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,308, reflecting strong market interest and confidence in the company's performance.
  • Recent analyst ratings indicate a consensus of "Moderate Buy," suggesting that many experts believe the stock has potential for growth.
  • Insider ownership is relatively low at 1.94%, which may indicate that the stock is accessible for new investors without significant insider influence on price movements.

Cons of Mettler-Toledo International

  • Insider sales, such as the recent sale of 300 shares by the CFO, could indicate a lack of confidence in the stock's short-term performance.
  • The company has experienced a significant decrease in insider ownership, which may raise concerns about long-term commitment from key executives.
  • Despite positive analyst ratings, the stock has seen fluctuations, which could lead to volatility and risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.07 billion
P/E Ratio
33.29
Consensus Rating
Hold
Consensus Price Target
$1,328.33 (+1.1% Upside)
Volume
146,230 shares
Average Volume
137,698 shares
Today's Range
$1,304.00
$1,327.01
50-Day Range
$1,191.70
$1,324.30
52-Week Range
$946.69
$1,486.76
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$28.00 +0.24 (+0.85%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$28.00 0.00 (0.00%)
As of 10/3/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $27.86, which reflects a stable market position and potential for growth.
  • Recent institutional investments, such as Ballentine Partners LLC increasing their holdings by 138.2%, indicate strong confidence in the company's future performance.
  • Koninklijke Philips reported earnings that exceeded analysts' expectations, showcasing its ability to generate revenue effectively.

Cons of Koninklijke Philips

  • The stock has a high P/E ratio, which may suggest that it is overvalued compared to its earnings.
  • Recent downgrades from analysts, such as a shift from a "buy" to a "hold" rating, could indicate potential challenges ahead.
  • Despite positive earnings, the company has a relatively low net margin, which may limit profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.96 billion
P/E Ratio
147.39
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
1.02 million shares
Average Volume
641,004 shares
Today's Range
$27.78
$28.07
50-Day Range
$25.65
$28.63
52-Week Range
$21.48
$32.62
Dividend Yield
2.94%
DexCom stock logo

50. DexCom NASDAQ:DXCM

$67.05 +0.61 (+0.92%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$67.05 0.00 (0.00%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $80, reflecting a stable valuation in the medical device sector.
  • DexCom, Inc. has seen significant institutional interest, with 97.75% of its stock owned by institutional investors, indicating strong confidence from major financial entities.
  • Recent sales of shares by insiders, while notable, represent a small percentage of total ownership, suggesting that executives still have substantial confidence in the company's future.

Cons of DexCom

  • Insider sales totaling 6,849 shares in the last quarter may raise concerns about executives' confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a recent decrease in ownership percentages among executives, which could signal potential volatility.
  • With only 0.32% of the stock owned by insiders, there may be a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.29 billion
P/E Ratio
46.56
Consensus Rating
Moderate Buy
Consensus Price Target
$98.32 (+46.6% Upside)
Volume
4.44 million shares
Average Volume
6.49 million shares
Today's Range
$66.37
$67.63
50-Day Range
$66.08
$89.53
52-Week Range
$57.52
$93.25
Dividend Yield
N/A